Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic marker and a potential therapeutic target

Oncology Reports

Volumn 25, Issue 6, 2011, Pages 1517-1524

  Lee, Jeeyun ^a   Seo, Jin Won ^a   Jun, Hyun Jung ^a   Ki, Chang Seok ^a   Park, Se Hoon ^a   Park, Young Suk ^a   Lim, Ho Yeong ^a   Choi, Min Gew ^a   Bae, Jae Moon ^a   Sohn, Tae Sung ^a   Noh, Jae Hyung ^a   Kim, Sung ^a   Jang, Hey Lim ^b   Kim, Ji Youn ^b   Kim, Kyoung Mee ^a   Kang, Won Ki ^a   Park, Joon Oh ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Gastric cancer; MET amplification; MET kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENE AMPLIFICATION; GENE DUPLICATION; GENE NUMBER; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE; ONCOGENE MET; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER; STOMACH SURGERY; SURVIVAL RATE; SURVIVAL TIME; TISSUE SECTION;

ADOLESCENT; ADULT; AGED; BLOTTING, WESTERN; CARCINOMA; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79954471845     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1219     Document Type: Article

References (21)

1. Cunningham D, Jost LM, Purkalne G and Oliveira J: ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer. Ann Oncol 16 (Suppl.) 1: i22-i23, 2005. (Pubitemid 40872975)
2. Inoue M and Tsugane S: Epidemiology of gastric cancer in Japan. Postgrad Med J 81: 419-424, 2005.
3. Bae JM WY, Jung KW and Park JG: Annual report of the Korea Central Cancer Registry Program 2000: based on registered data from 131 hospitals. Cancer Res Treat 34: 77-83, 2002.
4. Corso S, Comoglio PM and Giordano S: Cancer therapy: can the challenge be MET? Trends Mol Med 11: 284-292, 2005.
5. Ponzetto C, Giordano S, Peverali F, Delia Valle G, Abate ML, Vaula G and Comoglio PM: c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene 6: 553-559, 1991. (Pubitemid 21924118)
6. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H and Tahara E: Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 189: 227-232, 1992. (Pubitemid 23030031)
7. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T and Nakano H: The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85: 1894-1902, 1999.
8. Inoue T, Kataoka H, Goto K, Nagaike K, Igami K, Naka D, Kitamura N and Miyazawa K: Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci 95: 803-808, 2004. (Pubitemid 39545586)
9. Huang TJ, Wang JY, Lin SR, Lian ST and Hsieh JS: Overexpression of the c-met protooncogene in human gastric carcinoma-correlation to clinical features. Acta Oncol 40: 638-643, 2001.
10. Nessling M, Solinas-Toldo S, Wilgenbus KK, Borchard F and Lichter P: Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2. Genes Chromosomes Cancer 23: 307-316, 1998. (Pubitemid 28507370)
11. Sakakura C, Mori T, Sakabe T, Ariyama Y, Shinomiya T, Date K, Hagiwara A, Yamaguchi T, Takahashi T, Nakamura Y, Abe T and Inazawa J: Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosomes Cancer 24: 299-305, 1999. (Pubitemid 29115867)
12. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM and Mendel DB: A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63: 7345-7355, 2003. (Pubitemid 37413476)
13. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J and Haber DA: Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 103: 2316-2321, 2006. (Pubitemid 43271667)
14. Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, Park SH, Lee SH, Kim K, Park JO, Kim WS, Jung CW, Park YS, Im YH, Sohn TS, Noh JH, Heo JS, Kim YI, Park CK and Park K: An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 63: 1279-1285, 2005. (Pubitemid 41628018)
15. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM and Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725-730, 2001.
16. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC and Janne PA: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007. (Pubitemid 46799492)
17. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH and Pao W: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104: 20932-20937, 2007.
18. Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J and Jovin TM: Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65: 473-482, 2005.
19. Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N and Nishio K: Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. Cancer Sci 98: 1498-1503, 2007. (Pubitemid 47241776)
20. Eder JP, Heath L, Appleman L, Shapiro G, Wang D, Malburg L, Zhu AX, Leader T, Wolanski A and LoRusso P: Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. J Clin Oncol, 2007 ASCO Annual Meeting Proc. Part I. Vol 25, No. 18S (June 20 Suppl): 3526, 2007.
21. Jhawer MP, Kindler HL, Wainberg ZA, et al: Preliminary activity of GSK1363089 (formerly XL880), a Dual c-MET/ VEGFR2 inhibitor, in poorly differentiated gastric cancer (PDGC): interim results of a multicenter phase II study. 2008 ASCO Annual Meeting Proc. J Clin Oncol 26 (18S): abs. 4572, 2008.